Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
- Barr, Paul M.
- Owen, Carolyn
- Robak, Tadeusz
- Tedeschi, Alessandra
- Bairey, Osnat
- Burger, Jan A
- Hillmen, Peter
- Coutre, Steve E.
- Dearden, Claire
- Grosicki, Sebastian
- McCarthy, Helen
- Li, Jian-Yong
- Offner, Fritz
- Moreno, Carol
- Zhou, Ccathy
- Hsu, Emily
- Szoke, Anita
- Kipps, Thomas J.
- Ghia, Paolo
- Universitat Autònoma de Barcelona
DOIAbstract
Altres ajuts: AstraZeneca; TG Therapeutics; Acerta; Janssen.We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukemia (CLL) studies. Patients
Add to ORKG